Role of cell-free DNA in haematological malignancies.


Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 13 12 2020
accepted: 17 01 2021
pubmed: 3 3 2021
medline: 11 11 2021
entrez: 2 3 2021
Statut: ppublish

Résumé

Cell-free DNA (cfDNA) consists of fragments of double stranded DNA that are found in the circulation. They are released from the apoptosis of both normal haemopoietic cells and malignant cells. The use of cfDNA from easily accessible peripheral blood samples has created a new strategy in studying molecular genomics in haematological malignancies. Its use in diagnosis, prognosis and monitoring potentially precludes the need for repeated tissue samples, i.e., bone marrow biopsy or primary tissue biopsy. It also potentially provides a more comprehensive analysis of the disease as cfDNA are released from tumours from multiple sites of the body. While cfDNA research is still in its infancy, given its potential and the expansion in next generation sequencing (NGS) it has attracted a lot of attention in recent years. This review will focus on acute leukaemia, multiple myeloma and lymphoma and the potential diagnostic and prognostic implications of cfDNA, its role in response assessment and in detection of disease relapse.

Identifiants

pubmed: 33648721
pii: S0031-3025(21)00049-0
doi: 10.1016/j.pathol.2021.01.004
pii:
doi:

Substances chimiques

Cell-Free Nucleic Acids 0
DNA 9007-49-2

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

416-426

Informations de copyright

Copyright © 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Auteurs

Jun K Lim (JK)

Department of Haematology, The Canberra Hospital, Canberra, ACT, Australia.

Bryone Kuss (B)

Department of Molecular Medicine and Genetics, Flinders University/Flinders Medical Centre, SA Pathology Laboratories, Adelaide, SA, Australia.

Dipti Talaulikar (D)

Department of Haematology, The Canberra Hospital, Canberra, ACT, Australia; College of Health and Medicine, Australian National University, Canberra, ACT, Australia. Electronic address: dipti.talaulikar@act.gov.au.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH